Intractable diarrhoea associated with secondary amyloidosis in rheumatoid arthritis

Yasuaki Okuda, Kiyoshi Takasugi, Tetsu Oyama, Hiroko Oyama, Shigeru Nanba, Takeshi Miyamoto

Abstract

Objective—To examine the clinical characteristics of intractable diarrhoea associated with secondary amyloidosis in rheumatoid arthritis (RA).

Methods—Of 179 RA patients with biopsy confirmed secondary amyloidosis, 24 cases (23 women and one man) with intractable diarrhoea lasting for more than one month were retrospectively evaluated.

Results—The mean (SD) duration of diarrhoea was 87 (64) days. Prodromal symptoms of gastrointestinal dysfunction (n = 21) and impaired peristalsis (n = 16) were observed. Laboratory data showed hypoproteinaemia (4.7 (0.85) g/dl) caused by malabsorption or protein loss and high values of C reactive protein (17.0 (9.3) mg/dl). Recurrence of intractable diarrhoea (n = 4) and transition from intractable diarrhoea to other gastrointestinal problems of amyloidosis (ischaemic colitis (n = 2) and intestinal pseudo-obstruction (n = 4)) were observed. In 19 patients (25 episodes) the duration of intravenous hyperalimentation at remission (18 episodes) was 68 (52) days. Corticosteroid pulse therapy was administered to 10 patients (11 times) and the time elapsed from the end of corticosteroid pulse therapy to the end of diarrhoea was 18 (14) days. One and five year survival rates after the onset of intractable diarrhoea were 73.4% and 38.9%. Seven of 13 patients (54%) had died as a result of infectious diseases.

Conclusion—Intractable diarrhoea associated with secondary amyloidosis in RA is a serious clinical entity and the prognosis is poor. Although it is assumed that intravenous hyperalimentation treatment and corticosteroid pulse therapy are favourable regimens for intractable diarrhoea, the patients should be monitored for possible infectious complications.

(Ann Rheum Dis 1997;56:535-541)

Secondary amyloidosis is a disease characterised by extracellular deposition of amyloid A protein, which is the result of excessive generation and abnormal degradation of serum amyloid A (SAA).¹

Recent clinical studies have shown that the prevalence of amyloidosis proved by biopsy in rheumatoid arthritis (RA) patients is about 10%.²⁻⁵ Among the complications of RA, secondary amyloidosis is one of the most

severe complications in the late stages of RA because of its poor prognosis.⁶⁻⁸

Secondary amyloidosis commonly affects the gastrointestinal tract as well as the kidneys, as shown by various clinical symptoms that include anorexia, nausea, vomiting, feeling of abdominal fullness, abdominal pain, diarrhoea, melaena, and perforation of the gastrointestinal tract.⁴⁻⁹⁻¹³ In particular prolonged intractable diarrhoea is severe, distressing, and often unresponsive to treatment. Thus, it is essential to clarify the clinical characteristics, the treatment, and the prognosis of intractable diarrhoea associated with secondary amyloidosis in patients with RA. While case reports have been reported,¹⁴⁻¹⁷ we believe this is the first attempt to describe a retrospective series in a defined population with secondary amyloidosis caused by RA. In this case record review, clinical features and prognosis are examined.

Methods

PATIENT SELECTION

The inclusion criteria for this retrospective study were as follows: RA diagnosed according to the criteria for the classification of RA of the American College of Rheumatology (formerly the American Rheumatism Association) of 1987,¹⁸ and the presence of intractable diarrhoea. Intractable diarrhoea was defined as sustained watery diarrhoea that did not respond to treatment with the antidiarrhoeal drugs such as albumin tannate, berberine, loperamidehydrochloride for more than one month and having no other cause of diarrhoea than secondary amyloidosis, such as bacterial enterocolitis or pancreatic diseases. The termination of diarrhoea was defined when a formed stool was observed.

For the patients who survived, the mean (SD) time from the diagnosis of amyloidosis to the final assessment was 1606 (1172) days (median 1681, 102-3260), and the mean (SD) time from the onset of intractable diarrhoea to the final assessment was 1494 (1221) days (median 1684, 56-3312).

STUDY DESIGN

Tissue staining with Congo red and antiserum against amyloid A protein were routinely performed to establish the diagnosis of secondary amyloidosis.

All the patients with intractable diarrhoea had deposits of amyloid A protein on the gastrointestinal tract mucosa (stomach, duodenum or colon). When specimens confirmed positive staining for amyloid deposits on gastrointestinal tracts, they were divided

Department of Internal Medicine, Centre for Rheumatic Diseases, Dohgo Spa Hospital, Matsuyama, Ehime, Japan

Y Okuda
K Takasugi
T Oyama
H Oyama
S Nanba
T Miyamoto

Correspondence to:
Dr Y Okuda, Department of Internal Medicine, Centre for Rheumatic Diseases, Dohgo Spa Hospital, 21-21 Otsu Dohgo- Himezuka Matsuyama-City, Ehime 790, Japan.

Accepted for publication
11 June 1997

Table 1 Clinical features in 24 patients with rheumatoid arthritis and intractable diarrhoea caused by secondary amyloidosis

Age at diagnosis of amyloidosis, mean (SD) y (median; range)	57 (9) (57; 40–74)
Duration of arthritis at diagnosis of amyloidosis, mean (SD) y (median; range)	13 (5) (13; 3–22)
Articular erosions (%)	100
Rheumatoid factor (%) [*]	92
Lansbury activity index mean (SD) (median; range) [†]	69 (21) (79; 38–119)
CRP, mg/dl mean (SD) (median; range) [‡]	8.9 (5.6) (11.6; 0.6–22.5)
CRN, mg/dl mean (SD) (median; range) [‡]	0.6 (0.2) (0.8; 0.3–1.2)
Proteinuria (%)	17
Haematuria (%)	8

CRP=C reactive protein; CRN=creatinine. ^{*}Rheumatoid factor in serum was measured by the rheumatoid arthritis haemagglutination test. [†]Patients were evaluated for four parameters (morning stiffness, grip strength, joint count, and erythrocyte sedimentation rate) at the nearest point before onset of intractable diarrhoea. [‡]Values at nearest point before onset of intractable diarrhoea.

into two groups according to the degree of deposits.⁵ The classification of slight amyloid deposits was defined as the minimum positive staining observed under high power magnification (×200) limited to either the lamina propria mucosae or to the submucosa. All the other types of positive staining were classified as the severe deposits group.

RA activity was evaluated by Lansbury activity index calculated from morning stiffness, erythrocyte sedimentation rate, grip strength, and joint score.¹⁹ Patients were evaluated for RA activity at the nearest point before the onset of intractable diarrhoea. The presence of prodromal gastrointestinal symptoms such as abdominal pain, nausea, anorexia or transient diarrhoea and the presence of other possible causes of intractable diarrhoea were investigated from the clinical records.

We investigated the cases in which intestinal pseudo-obstruction or ischaemic colitis occurred during the course or after the improvement of intractable diarrhoea. The diagnosis of ischaemic colitis was made when abdominal pain and melaena occurred and colonoscopic examination showed mucosal changes (oedema, redness) and longitudinal ulcers consistent with ischaemic colitis. The diagnosis of intestinal pseudo-obstruction was

based on the presence of typical clinical symptoms (abdominal distension, complete failure to evacuate stool, and flatus) and abdominal x ray findings (gaseous distension of small intestine and colon) consistent with intestinal pseudo-obstruction.

STATISTICAL ANALYSIS

The survival time was calculated from the date of the onset of intractable diarrhoea. For the cases of repeated, multiple episodes of intractable diarrhoea, the survival time was calculated from the date of onset of the first episode.

In comparison with the non-intractable diarrhoea group the survival time was calculated from the date on which the amyloidosis was diagnosed. The non-intractable diarrhoea group consists of all the patients with secondary amyloidosis and RA who had never experienced intractable diarrhoea. Survival was assessed by life table analysis. Survival curves were calculated by the Kaplan-Meier method. The prognostic value of factors (measured at the onset of intractable diarrhoea) for survival was investigated using log rank tests. Correlations were sought using a ranked Spearman correlation coefficient. Statistical evaluation of the data was performed using StatView J4.05 software for Macintosh. Probabilities <0.05 were considered significant.

Results

CLINICAL FEATURES

During the years from 1985 to 1995, a total of 3415 patients with RA were seen at the Centre for Rheumatic Diseases of Dohgo Spa Hospital.

Among the 179 cases of biopsy confirmed secondary amyloidosis treated at our centre between 1985 and 1995, there were 24 patients (23 women and one man) who fulfilled the inclusion criteria. In 15 cases, diagnosis of sec-

Table 2 Clinical findings and laboratory data of the 24 rheumatoid arthritis patients with intractable diarrhoea caused by secondary amyloidosis

Patient	Age [*] /sex	Duration of diarrhoea (days)	Frequency of diarrhoea (times)	Nadir TP [†] (g/dl)	Nadir Alb [†] (g/dl)	Max CRP [‡] (mg/dl)
1	56/F	54	6	3.8	1.8	13.3
2	41/F	32	5	6.2	3.1	6.3
3	53/F	81	8	5.4	2.2	18.7
4	60/F	69	5	5.6	2.4	12.0
5	74/F	135	16	3.4	1.3	22.5
6	57/F	83	7	5.4	2.5	8.3
7	67/F	36	6	4.5	2.3	8.5
8	46/F	50	8	5.5	2.6	10.7
9	68/F	94	9	4.8	1.7	6.5
10	40/F	116	6	5.1	2.4	24.4
11	53/F	177	10	3.0	1.5	24.3
12	56/F	258	8	4.8	2.6	18.4
13	50/F	268	11	4.8	1.9	39.5
14	71/F	80	8	4.7	2.6	8.2
15	44/F	70	4	4.5	2.3	21.5
16	71/M	74	6	3.3	1.9	25.2
17	54/F	41	8	4.0	2.4	22.0
18	60/F	42	5	5.5	2.3	33.9
19	58/F	46	8	5.4	2.7	15.9
20	54/F	54	9	4.4	1.6	9.4
21	61/F	62	5	5.2	2.4	7.1
22	59/F	92	7	3.7	2.0	8.5
23	61/F	41	5	5.0	2.2	13.2
24	51/F	36	6	4.0	1.9	29.6

TP=total protein; Alb=albumin; CRP=C reactive protein. ^{*}Age at diagnosis of amyloidosis. [†]Nadir values during the course of intractable diarrhoea. [‡]Maximum values during the course of intractable diarrhoea.

ondary amyloidosis was established at the time when they developed intractable diarrhoea. Gastrointestinal symptoms such as abdominal pain, anorexia but not persistent diarrhoea led to the diagnosis in five cases. The remaining four cases were discovered on routine endoscopic gastrointestinal screening.

Table 1 summarises the main RA features of the 24 cases. Only one case showed the creatinine concentration in excess of 1.0 mg/dl at the onset of intractable diarrhoea. Minor proteinuria (<1 g/24h) was seen in four cases. None of the cases showed heart failure, low voltage electrocardiogram or hypothyroidism. Many cases showed increased Lansbury activity indices and C reactive protein values. Prodromal symptoms of gastrointestinal dysfunction were observed in 21 cases (88%), and the symptoms were repeatedly observed from one year or several months before the onset of intractable diarrhoea.

Other possible causes of the induction of intractable diarrhoea were recognised in six cases including three cases of infection, two cases of operation, and one case of extraarticular manifestation (myocarditis). The three episodes of infection were purulent arthritis of left knee, meningitis caused by *Candida albicans*, and hepatitis caused by cytomegalovirus. The two cases of intractable diarrhoea caused by operation started to manifest intractable diarrhoea 14 days after the synovectomy of bilateral knees and 24 days after the fusion of cervical spine, respectively. Greatly increased C reactive protein values were observed in all six cases before the onset of intractable diarrhoea (median; 14.4 mg/dl, range; 6.3–22.5 mg/dl).

The abdominal features during the course of intractable diarrhoea included pain in 22 cases (92%), nausea in 21 (88%), vomiting in 20 (83%), and distension in 16 (67%).

Table 2 summarises the clinical findings and the laboratory data of the 24 cases. The duration of diarrhoea was 87 (64) days (median 150, range 32–268) and the frequency of diarrhoea was 7 (3) times/day (median 10 times/day, range 4–16 times/day). The nadir total protein concentration and the nadir albumin concentration during the course of diarrhoea were 4.7 (0.85) g/dl (median 4.6 g/dl, range 3.0–6.2 g/dl) and 2.2 (0.43) g/dl (median 2.2 g/dl, range 1.3–3.1 g/dl), respectively. The maximum C reactive protein value during the course of intractable diarrhoea was very high (17.0 (9.3) mg/dl; median 22.9 mg/dl, 6.3–39.5 mg/dl).

Table 3 summarises the endoscopic findings of 16 cases in which upper gastrointestinal or colon endoscopy was performed during the course of intractable diarrhoea. Abnormal findings were observed in the stomach or duodenum or colon in all the cases. Coarse mucosal appearance such as fine granular elevation or irregular mucosa was seen in 12 cases (75%) and mucosal injuries (ulcer, erosion, bleeding or redness) were observed in 11 cases (69%) in upper gastrointestinal or colon endoscopy (figs 1 and 2). On the other hand, in the non-intractable diarrhoea patients

Table 3 Endoscopic findings in rheumatoid arthritis patients during intractable diarrhoea caused by secondary amyloidosis

Patient no	Endoscopic findings		
	Stomach	Duodenum	Colon
2	NA	ER,RED	
3	ER,RED	ER,RED	ER,RED (des,sig,rec)
4	CMA,BL	CMA	
5	CMA	CMA	CMA (rec)
7	NA	ER,CMA	NA
9	UL,ER	UL,CMA	NA
10	NA	CMA	NA
11	BL,UL	CMA	CMA (des)
12	CMA	CMA	
13	CMA,ER	CMA	ER,RED (rec)
18	CMA	NA	
19	RED	CMA	NA
20	UL,RED	NA	
21	RED,BL,CMA	NA	
22	CMA	CMA	
23	RED	NA	ER,RED (rec)

CMA = coarse mucosal appearance; ER = erosion; UL = ulcer; RED = redness; BL = bleeding; NA = no abnormality; rec = rectum; sig = sigmoid colon; des = descending colon.

on whom upper gastrointestinal or colon endoscopy were performed at the time of diagnosis of secondary amyloidosis, coarse mucosal appearance was seen in 21 of 121 cases (17%), and mucosal injuries were observed in 67 of 121 cases (55%).

Gastroduodenal biopsies were conducted on all 16 cases and considerable deposits of amyloid were found in gastrointestinal tissues. In the eight cases in which no endoscopy was performed during the course of intractable diarrhoea, considerable deposits of amyloid from gastrointestinal tracts had been found before the onset of intractable diarrhoea. On the other hand, in the non-intractable diarrhoea patients who were diagnosed as secondary amyloidosis by gastrointestinal biopsy considerable deposits of amyloid were observed in 63 of 121 patients (52%).

Recurrence of intractable diarrhoea after remission or other types of gastrointestinal manifestations of amyloidosis was observed in nine cases. Figure 3 shows the transition patterns. In four cases of recurrent intractable diarrhoea, six episodes occurred and the time

Figure 1 Multiple erosions, redness, and coarse irregular elevated mucosa are seen in the antrum of the stomach.

Figure 2 Endoscopy shows fine granular elevations in the second portion of the duodenum.

elapsed before the next episode was 6 (2.8) months (3–10). Ischaemic colitis after the remission of intractable diarrhoea was observed in two cases and the time elapsed from the remission of intractable diarrhoea until the onset of ischaemic colitis was 26 and 24 months, respectively. Intestinal pseudo-obstruction during the course of intractable diarrhoea was observed in four cases, among which one case showed intestinal pseudo-obstruction during the third episode of intractable diarrhoea.

Treatment regimens of intractable diarrhoea were determined by the physician responsible for care. However, for the cases with frequent watery diarrhoea and having severe nausea and severe hypoalbuminaemia, the following treatment regimens were conducted (table 4). To allow the impaired intestine to rest and to reduce intestinal inflammation, these patients received intravenous hyperalimentation in combination with a moderate dose of corticosteroids (10 to 30 mg/day of prednisolone). For cases showing no remission of watery diarrhoea with this regimen, corticosteroid pulse therapy (100 mg $\times$ 3 days of betamethasone or 125 mg $\times$ 3 days of methylpred-

Patterns (Patient number, interval of episodes of gastrointestinal amyloidosis (months))		Cases
Diarrhoea	→ pseudo-obstruction (no interval)	3
Diarrhoea	→ diarrhoea (patient 3, 4 months; patient 11, 7 months)	2
Diarrhoea	→ ischaemic colitis (patient 5, 26 months; patient 12, 24 months)	2
Diarrhoea	→ diarrhoea → diarrhoea (patient 10, 3 months and 10 months)	1
Diarrhoea	→ diarrhoea → diarrhoea → pseudo-obstruction (patient 7, 4 months and 8 months)	1

Figure 3 Patterns of relapse of intractable diarrhoea and transition from intractable diarrhoea to other types of gastrointestinal manifestations of amyloidosis (ischaemic colitis or intestinal pseudo-obstruction).

Figure 4 Survival rate of the 24 rheumatoid arthritis patients with intractable diarrhoea associated with secondary amyloidosis.

nisolone) was administered after confirmation of absence of infectious diseases.

Intravenous hyperalimentation treatment was performed in 19 cases, 25 times, and the duration of intravenous hyperalimentation treatment of 18 episodes at the remission, excluding the deceased cases, was 6852 days (median 126, range 29–223).

The corticosteroid pulse therapy was conducted in 10 cases, 11 times. The duration of diarrhoea from its onset to the corticosteroid pulse therapy in nine cases with 10 episodes, excluding one deceased case, was 77 (76) days (median 135, range 17–253) and the duration from the end of corticosteroid pulse therapy to the end of diarrhoea was 18 (14) days (median 26.5, range 3–50).

Thirteen patients (54%) died during the study period. Table 5 summarises the causes of death. The cause of death was confirmed mainly by the clinical record. The duration from the diagnosis of amyloidosis until death and that from the onset of intractable diarrhoea until death were 843 (618) days (median 1138, range 142–2133) and 706 (728) days (median 1089, range 40–2138) respectively. Seven patients died during the course of intractable diarrhoea. One died of congestive heart failure during the third course of intractable diarrhoea. Another died because of septicæmia and one died of pneumonia after transition to intestinal pseudo-obstruction. One patient with septicæmia died after the transition to intestinal pseudo-obstruction during the course of the third episode of intractable diarrhoea.

Figure 5 Survival of the 24 rheumatoid arthritis patients with intractable diarrhoea associated with secondary amyloidosis, according to C reactive protein (CRP) ≥ 17 mg/dl or CRP < 17 mg/dl.

Table 4 Treatment of intractable diarrhoea caused by secondary amyloidosis in 24 rheumatoid arthritis patients

Patient	IVH	IVH duration (days)	CS maximum dose (mg/day) *	CS pulse	Duration of diarrhoea (days) †	Duration of pulse (days) ‡	Outcome §
1	+	35	20	—			D
2	—		10	—			S
3	+	44	10	—			S
4	+	73	10	M125	42	17	S
5	+	87	20	—			S
6	—		30	—			S
7	—		5	—			S
	+	40	25	—			S
	+	21	20	M125	92	14	D
8	—		0	—			S
9	+	33	15	—			S
10	+	76	20	—			S
	+	39	20	—			D
11	+	182	20	B100	166	11	S
	+	64	20	B100	66	23	S
12	+	223	10	B100	253	3	S
13	+	151	5	—			D
14	+	51	20	B100	30	50	S
15	+	27	20	—			D
16	+	37	10	—			D
17	+	4	17	M125	34	—	D
18	+	40	10	—			S
19	+	30	10	M125	17	29	S
20	—		0	—			S
21	—		10	M125	59	3	S
22	+	56	5	—			S
23	+	29	20	M125	30	11	S
24	+	50	20	B100	19	17	S

IVH=intravenous hyperalimentation, CS=corticosteroid, M125=methylprednisolone 125 mg $\times$ 3 days, B100=betamethazone 100 mg $\times$ 3 days, S=survival, D=death. *Maximum daily dose of prednisolone. †Duration of diarrhoea before start of corticosteroid pulse treatment. ‡Duration of diarrhoea after the end of corticosteroid pulse treatment. §Outcome of patient during the course of intractable diarrhoea. || Denotes transition from intractable diarrhoea to intestinal pseudo-obstruction before death.

SURVIVAL ANALYSIS

Figure 4 shows the overall survival curve. The percentages of patients who survived at least one, three, and five years after the onset of intractable diarrhoea were 73.4%, 57.7%, 38.9%, respectively.

Analysis of the prognostic value of factors for survival indicated that both a high C reactive protein value (CRP ≥ 17 mg/dl (mean value)) during the course of intractable diarrhoea ($p=0.0395$) (fig 5) and intravenous hyperalimentation treatment ($p=0.0484$) were significantly correlated with decreased survival. Their five year survival rates were 11.8% ($n=11$), versus 63.9% ($n=13$) when C reactive protein was <17 mg/dl and 27.4% ($n=19$), versus 75.0% ($n=5$) with no intravenous hyperalimentation treatment, respectively. Hypoproteinaemia (total protein <4.7 g/dl) and short duration of arthritis at diagnosis of amyloidosis (<13 years) were associated with a trend toward decreased survival ($p=0.101$ and 0.1566 , respectively). But no correlation was seen between survival time and concentration of total protein ($p=0.346$, $p=0.0974$) or duration of arthritis at diagnosis of amyloidosis ($p=0.204$, $p=0.3274$). We found no

Table 5 Cause of death of 13 rheumatoid arthritis patients with intractable diarrhoea caused by secondary amyloidosis

Death during the course of intractable diarrhoea	
Septicaemia	4
Pneumonia	2
Congestive heart failure	1
Death during the follow up	
Chronic renal failure	3
Pneumonia	1
Pneumonitis	1
Unknown (sudden death at home)	1

Figure 6 Survival of 179 patients with rheumatoid arthritis associated with secondary amyloidosis, according to the presence or absence of intractable diarrhoea.

significant association between decreased survival and RA features before the onset of intractable diarrhoea (Lansbury activity index, the concentration of C reactive protein, gastrointestinal symptoms), duration of diarrhoea, frequency of diarrhoea, hypoalbuminaemia, the concentration of creatinine, relapse of intractable diarrhoea or transition to other types of gastrointestinal manifestation of amyloidosis and corticosteroid pulse therapy. Although not statistically significant by log rank test ($p=0.0704$), survival curves from the diagnosis of secondary amyloidosis showed lower values in the intractable diarrhoea group than in the non-intractable diarrhoea group (five year survival, 47% versus 61.1%) (fig 6).

Discussion

There is no detailed description of the clinical characteristics of patients with RA before the onset of intractable diarrhoea associated with secondary amyloidosis in previous case reports.¹⁴⁻¹⁷ Our present retrospective study showed that before the onset of diarrhoea, most patients showed high activity of arthritis and repeated prodromal gastrointestinal symptoms. Furthermore, some cases showed possible causes of induction of intractable diarrhoea (that is, operation, infection or extraarticular manifestation). SAA, which is the precursor of amyloid A protein, is known to be synthesised in the liver and the process is stimulated by macrophage derived cytokines such as interleukin 1, interleukin 6 or tumour necrosis factor, thus it rapidly increases in blood at the time of acute inflammation in parallel with acute phase proteins such as C reactive protein.²⁰ It is considered that high activity of arthritis, infection, surgery and extraarticular manifestation of RA induce a rapid increase of SAA and promote the deposit of amyloid, which might contribute to the onset of intractable diarrhoea.

With regard to renal function, most patients had normal values of creatine. Even in one patient who had increased concentrations of creatine at the time of the onset of intractable diarrhoea, those values returned to normal after recovery from dehydration. It is generally assumed that intractable diarrhoea tends to manifest earlier than renal dysfunction. In fact, in 15 cases (63%) the opportunity to diagnose amyloidosis was the onset of intractable

diarrhoea. Other opportunities to diagnose amyloidosis were at the time of the endoscopic upper gastrointestinal screening of amyloidosis and the onset of other digestive symptoms. There was no case of nephropathy such as renal failure or massive proteinuria before the onset of intractable diarrhoea.

With regard to clinical symptoms, abdominal pain, nausea and vomiting were seen in almost all cases. Abdominal distension with decreased bowel sounds on auscultation were recognised in about two thirds of the cases, which suggested the impaired peristalsis resulted from amyloid deposit,²¹ a characteristic finding of gastrointestinal amyloidosis.

During the course of diarrhoea, all cases showed severe hypoproteinaemia and hypoalbuminaemia. These results suggested malabsorption²² or protein loss.¹⁴ Moreover, highly increased values of C reactive protein during the clinical course were pathognomonic of intractable diarrhoea. The increased value of C reactive protein is assumed to be caused by severe intestinal inflammation. And we speculate that ischaemia of the intestinal mucosa and gastrointestinal infection are the causes of intestinal inflammation. With regard to infection, no causative bacteria such as *Shigella*, *Salmonella*, *Vibrio* or enteropathogenic *Escherichia coli* were detected in faeces culture. However, we could not perform bacteriological examination of jejunal aspirate. And we did not examine stool toxin of *Clostridium difficile* in three cases (case 2,16,17) who had been given antibiotics before the onset of intractable diarrhoea. Thus, it cannot be denied that change or increase of some kind of intestinal bacterial flora or viral infection may have triggered the gastrointestinal inflammation.

From these clinical symptoms and abnormal laboratory data, the impaired motility and inflammation of the intestine are assumed to be important pathogenic factors of intractable diarrhoea. It is probable that amyloid infiltration of the intestinal smooth muscle²³ or gastrointestinal neuropathy with amyloid involvement of the autonomic nerves²¹ caused impaired motility of the intestines.

Abnormal findings were noted in all the patients who underwent gastrointestinal endoscopy. The coarse mucosal appearance reported by Tada²⁴ and Shimada² were observed in 75% of the cases. These findings are considered to have been caused by amyloid deposits. Although mucosal injuries are highly suggestive of gastrointestinal tract inflammation caused by amyloidosis we must treat these abnormal lesions by considering the possibility that they were induced by drugs such as non-steroidal anti-inflammatory drugs.

Recurrence of intractable diarrhoea was observed in four of 24 cases (six episodes) and onset of ischaemic colitis in two. It was difficult in most of these cases to give anti-rheumatic drugs continuously because of the manifestation of gastrointestinal symptoms such as constipation, diarrhoea, feeling of abdominal fullness or nausea after the remission of the first episode of intractable diarrhoea and adverse reactions. Therefore, these patients

sustained high RA activities, leading to the recurrence of gastrointestinal amyloidosis. The patients whose condition worsened and presented symptoms of intestinal pseudo-obstruction were very serious, and three of four cases died. The transition from diarrhoea to intestinal pseudo-obstruction is considered as one of the most serious conditions showing severe gastrointestinal dysfunction.

Intractable diarrhoea was treated to allow the impaired intestines some rest and reduce intestinal inflammation. The patients who had severe nausea or vomiting and those with severe hypoproteinaemia received intravenous hyperalimentation in combination with a moderate dose of corticosteroids. Intravenous hyperalimentation was given to suppress exudation from digestive organs and rest the inflamed gastrointestinal tracts. Intravenous hyperalimentation had to be given for a comparatively long period of time until remission, but it was effective in many cases. There are some reports indicating the usefulness of intravenous hyperalimentation for severe diarrhoea caused by amyloidosis.^{15,16} Thus intravenous hyperalimentation is considered an appropriate regimen for severe cases. Patients who did not respond to intravenous hyperalimentation treatment and had diarrhoea for a long period of time, were given corticosteroid pulse therapy at the discretion of the physician responsible for care. Decrease of the frequency of diarrhoea or transition of watery diarrhoea to soft faeces was observed early after the end of corticosteroid pulse therapy. Especially, in the case of patients having long term diarrhoea (cases 11 and 12), diarrhoea stopped on days 11 and 3 after the end of corticosteroid pulse therapy, respectively, showing dramatic effects. Corticosteroid pulse therapy is supposed to strongly suppress the generation of SAA and intestinal exudation by reducing systemic and intestinal inflammation. A moderate dose of corticosteroids and corticosteroid pulse therapy are considered clinically effective in cases of diarrhoea caused by amyloidosis. On the other hand, however, corticosteroids are strong immunosuppressive agents, and therefore it is important to use them with caution for a short period of time while paying attention to infectious complications.

As for the causes of death during the course of intractable diarrhoea, the six of seven patients who died, died of infectious diseases. Bacterial translocation, that is, the transfer of bacteria from the intestine to the whole body was supposed to have occurred because of malnutrition and atrophy of intestinal villi caused by amyloid deposits and inflammation of the gastrointestinal mucosa. In addition, intractable diarrhoea is usually associated with hypogammaglobulinaemia, which makes the patients vulnerable to bacterial infections. The most frequent cause of death during the follow up was renal failure (three patients). Renal failure is the main cause of death for patients with secondary amyloidosis; thus, renal dysfunction is a poor prognostic factor in secondary amyloidosis.^{4,8,25} RA inflammation of the three

cases who died from renal failure was poorly controlled after remission of intractable diarrhoea and their renal function gradually deteriorated.

As for the long term prognosis, the five year survival rate of the 24 cases, from the onset of intractable diarrhoea, was as low as 38.9%. In particular, the five year survival rates of the 'group having highly increased C reactive protein values during the course of intractable diarrhoea' and the 'group requiring intravenous hyperalimentation treatment' were extremely low, 11.8% and 27.4%, respectively.

Why is the prognosis of patients with serious intractable diarrhoea so poor? There were patients who died of infectious diseases during the course of intractable diarrhoea, patients who had nausea or complained of abdominal fullness even after remission of diarrhoea, and patients who had persistent hypoproteinaemia or hypoalbuminaemia and were prone to suffer viral infections, such as herpes zoster, or showed poor compliance with anti-rheumatic drugs. Thus, the state of insufficient control of rheumatoid inflammation persisted and they would eventually develop gastrointestinal dysfunction or renal failure.

- 1 Friman C, Pettersson T. Amyloidosis. *Curr Opin Rheumatol* 1996;8:62-71.
- 2 Shimada Y, Tosa H, Terasawa K, Tanaka M. A gastrointestinal endoscopic study on secondary amyloidosis complicating rheumatoid arthritis. *Dig Endosc* 1992;4:37-49.
- 3 Tiitinen S, Kaarela K, Helin H, Kautiainen H, Isomaki H. Amyloidosis - Incidence and early risk factors in patients with rheumatoid arthritis. *Scand J Rheumatol* 1993; 22:158-61.
- 4 Okuda Y, Takasugi K, Oyama T, Onuma M, Oyama H. Amyloidosis in rheumatoid arthritis: clinical study of 124 histologically proven cases (in Japanese). *Ryumachi* 1994; 34:939-46.
- 5 Kobayashi H, Tada S, Fuchigami T, Okuda Y, Takasugi K, Matsumoto T, *et al.* Secondary amyloidosis in patients with rheumatoid arthritis: diagnostic and prognostic value of gastroduodenal biopsy. *Br J Rheumatol* 1996;35:44-9.
- 6 Browning MJ, Banks RA, Tribe CR, Hollingworth P, Kingwood C, Mackenzie JC, *et al.* Ten years' experience of an amyloid clinic - a clinicopathological survey. *Q J Med* 1985;54:213-27.
- 7 Janssen S, Van Rijswijk MH, Meijer S, Ruinen L, Van Der Hem GK. Systemic amyloidosis: a clinical survey of 144 cases. *Neth Med* 1986;29:376-85.
- 8 Gertz MA, Kyle RA. Secondary systemic amyloidosis: response and survival in 64 patients. *Medicine* 1991; 70:246-56.
- 9 Glenner GC. Amyloid deposits and amyloidosis. *N Engl J Med* 1980;302:1283-92.
- 10 Husby G. Amyloidosis and rheumatoid arthritis. *Clin Exp Rheumatol* 1985;3:173-80.
- 11 Kyle RA. Amyloidosis. *Baillieres Clin Hematol* 1982; 11:151-80.
- 12 Legge DA, Wollaegeer EE, Carlson HC. Intestinal pseudo-obstruction in systemic amyloidosis. *Gut* 1970;2:764-7.
- 13 Ishikawa Y, Ishii T, Masuda S, Asuwa N, Kuguchi H. Multiple penetrating colonic ulcers in secondary amyloidosis caused by rheumatoid arthritis. *Acta Pathol Jpn* 1993; 43:59-64.
- 14 Kawaguchi M, Koizumi F, Shimao M, Hirose S. Protein-losing enteropathy due to secondary amyloidosis of the gastrointestinal tract. *Acta Pathol Jpn* 1993;43:333-9.
- 15 Maruyama K, Akamatsu T, Owa O, Nakamura N, Fujimori Y, Hasebe O, *et al.* A case of secondary amyloidosis with clinical symptoms of acute enteritis (in Japanese). *Endosc Forum Dig Dis* 1993;9:284-8.
- 16 Ozawa T, Sato T, Nakano M, Arakawa M, Murasawa A. Cyclophosphamide and prednisolone treatment in gastrointestinal amyloidosis secondary to rheumatoid arthritis (in Japanese). *J Chubu Rheum Assoc* 1993;24:136-7.
- 17 Hashimoto M, Shingu M, Yoshikawa Y, Nonaka S, Wada T, Ichibanngase Y, *et al.* Amyloidosis of the small intestine secondary to rheumatoid arthritis and juvenile rheumatoid arthritis; reports of two cases (in Japanese). *Ryumachi* 1995;35:100-6.
- 18 Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, *et al.* The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988;31:315-24.
- 19 Lansbury J. Clinical appraisal of the activity index as a measure of rheumatoid activity. *Arthritis Rheum* 1968;11:599-605.
- 20 Falck HM, Maury CPJ, Teppo AM, Wegelius O. Correlation of persistently high serum amyloid A protein and C-reactive protein concentrations with rapid progression of secondary amyloidosis. *BMJ* 1983;286:1391-3.
- 21 Battle WM, Rubin MR, Cohen S, Snape WJ Jr. Gastrointestinal-motility dysfunction in amyloidosis. *N Engl J Med* 1979;301:24-5.
- 22 Petterson T, Wegelius O. Biopsy diagnosis of amyloidosis in rheumatoid arthritis. Malabsorption caused by intestinal amyloid deposits. *Gastroenterology* 1972;62:22-7.
- 23 Gilat T, Spiro HM. Amyloidosis and the gut. *Am J Dig Dis* 1968;13:619-33.
- 24 Tada S, Iida M, Iwashita A, Matsui T, Fuchigami T, Yamamoto T, *et al.* Endoscopic and biopsy findings of the upper digestive tract in patients with amyloidosis. *Gastrointest Endosc* 1990;36:10-4.
- 25 Hazenberg BC, Van Rijswijk MH. Clinical and therapeutic aspects of AA amyloidosis. *Baillieres Clin Rheumatol* 1994;8:661-90.